daptomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 783 103060-53-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • daptomycin
  • cidecin
  • cubicin
  • dapcin
  • daptomicina
  • daptomycine
  • daptomycinum
  • LY146032
  • LY-146032
  • deptomycin
A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.
  • Molecular weight: 1620.69
  • Formula: C72H101N17O26
  • CLOGP: -1.85
  • LIPINSKI: 3
  • HAC: 43
  • HDO: 22
  • TPSA: 702.02
  • ALOGS: -4.97
  • ROTB: 35

Drug dosage:

DoseUnitRoute
0.28 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1000 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.47 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.09 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 12, 2003 FDA CUBIST
July 1, 2011 PMDA MSD K.K

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood creatine phosphokinase increased 701.55 24.10 229 8241 30201 63450351
Eosinophilic pneumonia 391.45 24.10 84 8386 2127 63478425
Rhabdomyolysis 353.19 24.10 153 8317 43798 63436754
Eosinophilia 310.39 24.10 116 8354 22640 63457912
Pathogen resistance 235.21 24.10 69 8401 6329 63474223
Drug reaction with eosinophilia and systemic symptoms 211.75 24.10 99 8371 33737 63446815
Eosinophilic pneumonia acute 209.34 24.10 38 8432 388 63480164
Acute kidney injury 168.93 24.10 191 8279 263224 63217328
Product use in unapproved indication 156.00 24.10 153 8317 178927 63301625
Diffuse large B-cell lymphoma refractory 121.28 24.10 29 8441 1201 63479351
Antimicrobial susceptibility test resistant 113.80 24.10 16 8454 20 63480532
Chills 98.78 24.10 97 8373 113281 63367271
Bacteraemia 79.26 24.10 41 8429 17307 63463245
Drug resistance 73.80 24.10 43 8427 22890 63457662
Arthritis bacterial 70.36 24.10 28 8442 6435 63474117
Agranulocytosis 70.15 24.10 43 8427 25091 63455461
Neutropenia 69.17 24.10 100 8370 174905 63305647
Multiple organ dysfunction syndrome 63.77 24.10 56 8414 56696 63423856
Encephalopathy 62.16 24.10 47 8423 38573 63441979
Symmetrical drug-related intertriginous and flexural exanthema 60.82 24.10 14 8456 490 63480062
Pyrexia 59.84 24.10 167 8303 470311 63010241
Enterococcal infection 55.41 24.10 25 8445 7823 63472729
Endocarditis 52.63 24.10 22 8448 5728 63474824
Hepatic cytolysis 52.52 24.10 30 8440 15377 63465175
Cholestasis 52.25 24.10 38 8432 29396 63451156
Pancytopenia 51.44 24.10 64 8406 96869 63383683
Enterococcal bacteraemia 50.38 24.10 15 8455 1444 63479108
Rash 46.55 24.10 172 8298 560699 62919853
Toxic skin eruption 46.38 24.10 26 8444 12859 63467693
Off label use 45.67 24.10 194 8276 674268 62806284
Lactic acidosis 45.45 24.10 39 8431 38248 63442304
Drug interaction 44.68 24.10 96 8374 229035 63251517
Acute generalised exanthematous pustulosis 38.87 24.10 22 8448 11077 63469475
Device related infection 36.59 24.10 28 8442 23364 63457188
Leukopenia 36.22 24.10 48 8422 77242 63403310
Staphylococcal infection 35.30 24.10 35 8435 41221 63439331
Thrombocytopenia 34.96 24.10 68 8402 151089 63329463
Rash maculo-papular 34.86 24.10 31 8439 31865 63448687
Cardiac valve vegetation 34.61 24.10 8 8462 285 63480267
Staphylococcal bacteraemia 33.98 24.10 16 8454 5514 63475038
Tubulointerstitial nephritis 33.74 24.10 25 8445 19878 63460674
Myopathy 33.41 24.10 20 8450 11171 63469381
Joint swelling 32.78 24.10 3 8467 327663 63152889
Hyperoxaluria 32.64 24.10 7 8463 176 63480376
Abdominal discomfort 31.93 24.10 3 8467 320882 63159670
Candida infection 31.87 24.10 28 8442 28323 63452229
Blood creatinine increased 31.48 24.10 48 8422 87796 63392756
Alopecia 31.45 24.10 4 8466 337532 63143020
Interstitial lung disease 31.42 24.10 40 8430 61868 63418684
Pain 31.00 24.10 32 8438 740596 62739956
Cholestatic liver injury 30.84 24.10 12 8458 2598 63477954
Sepsis 30.78 24.10 65 8405 153058 63327494
Dermatitis exfoliative generalised 29.67 24.10 13 8457 3794 63476758
Neoplasm progression 29.50 24.10 30 8440 36398 63444154
Asymptomatic bacteriuria 29.29 24.10 7 8463 289 63480263
Fatigue 29.27 24.10 46 8424 887982 62592570
Eosinophil count increased 28.72 24.10 18 8452 10910 63469642
Myalgia 28.07 24.10 61 8409 146468 63334084
Headache 28.05 24.10 26 8444 633215 62847337
Drug intolerance 27.93 24.10 4 8466 308657 63171895
Osteomyelitis 27.86 24.10 25 8445 25995 63454557
Mixed liver injury 26.96 24.10 13 8457 4722 63475830
Blood culture positive 26.96 24.10 13 8457 4722 63475830
Fungal sepsis 26.93 24.10 9 8461 1261 63479291
Glomerular filtration rate abnormal 26.27 24.10 8 8462 831 63479721
Septic shock 26.15 24.10 38 8432 66591 63413961
Haemorrhagic disorder 26.11 24.10 8 8462 848 63479704
Acute respiratory distress syndrome 25.97 24.10 23 8447 23511 63457041
Disseminated intravascular coagulation 25.91 24.10 21 8449 19030 63461522
Immune effector cell-associated neurotoxicity syndrome 25.25 24.10 10 8460 2267 63478285
Product used for unknown indication 25.21 24.10 7 8463 525 63480027
Intervertebral discitis 25.08 24.10 11 8459 3217 63477335

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eosinophilic pneumonia 1419.42 20.02 321 14065 3180 34939365
Blood creatine phosphokinase increased 502.22 20.02 280 14106 44577 34897968
Antimicrobial susceptibility test resistant 401.93 20.02 77 14309 297 34942248
Eosinophilia 310.38 20.02 170 14216 26052 34916493
Drug reaction with eosinophilia and systemic symptoms 307.48 20.02 183 14203 32829 34909716
Eosinophilic pneumonia acute 281.41 20.02 61 14325 483 34942062
Rhabdomyolysis 229.89 20.02 204 14182 67959 34874586
Pathogen resistance 215.67 20.02 96 14290 9386 34933159
Acute kidney injury 155.43 20.02 368 14018 304620 34637925
Cardiac valve vegetation 150.82 20.02 36 14350 455 34942090
Product use in unapproved indication 144.71 20.02 208 14178 117291 34825254
Drug dispensed to wrong patient 133.26 20.02 33 14353 491 34942054
Minimum inhibitory concentration 126.19 20.02 26 14360 156 34942389
Staphylococcal bacteraemia 117.32 20.02 61 14325 8391 34934154
Chills 112.39 20.02 152 14234 80891 34861654
Multiple organ dysfunction syndrome 109.83 20.02 146 14240 76420 34866125
Therapeutic response delayed 107.72 20.02 29 14357 609 34941936
Hypersensitivity pneumonitis 100.91 20.02 34 14352 1561 34940984
Drug resistance 98.12 20.02 83 14303 25844 34916701
Agranulocytosis 97.92 20.02 80 14306 23741 34918804
Cholestasis 97.36 20.02 84 14302 26864 34915681
Interstitial lung disease 92.84 20.02 124 14262 65158 34877387
Drug ineffective for unapproved indication 87.85 20.02 75 14311 23640 34918905
Septic shock 83.66 20.02 124 14262 71710 34870835
Wrong patient received product 77.21 20.02 32 14354 2622 34939923
Bacteraemia 76.40 20.02 64 14322 19653 34922892
Pyrexia 74.62 20.02 302 14084 332711 34609834
Thrombocytopenia 74.25 20.02 184 14202 156063 34786482
Treatment failure 68.35 20.02 90 14296 46607 34895938
Diffuse alveolar damage 67.65 20.02 28 14358 2286 34940259
Alveolar lung disease 67.31 20.02 18 14368 368 34942177
Fatigue 66.50 20.02 35 14351 370618 34571927
Staphylococcal infection 65.61 20.02 74 14312 32686 34909859
Off label use 64.05 20.02 340 14046 419184 34523361
Expired product administered 60.82 20.02 29 14357 3312 34939233
Endocarditis 57.66 20.02 35 14351 6476 34936069
Pulmonary interstitial emphysema syndrome 57.47 20.02 17 14369 507 34942038
Rash maculo-papular 56.51 20.02 64 14322 28387 34914158
Candida infection 55.57 20.02 51 14335 17664 34924881
Enterococcal infection 55.38 20.02 39 14347 9267 34933278
Pulmonary eosinophilia 54.95 20.02 14 14372 235 34942310
Systemic candida 54.89 20.02 28 14358 3698 34938847
Toxic epidermal necrolysis 54.10 20.02 55 14331 21591 34920954
Hepatocellular injury 52.92 20.02 55 14331 22156 34920389
Hepatitis cholestatic 51.27 20.02 35 14351 7912 34934633
Wrong product administered 50.67 20.02 30 14356 5304 34937241
Product storage error 50.58 20.02 35 14351 8087 34934458
Product dispensing error 48.66 20.02 31 14355 6243 34936302
Diarrhoea 48.05 20.02 54 14332 389858 34552687
Fall 46.49 20.02 13 14373 202872 34739673
Sepsis 46.19 20.02 162 14224 166399 34776146
Intervertebral discitis 45.99 20.02 21 14365 2174 34940371
Lower respiratory tract infection 44.77 20.02 60 14326 31577 34910968
Pneumonitis 43.05 20.02 61 14325 33817 34908728
Aortoenteric fistula 42.44 20.02 10 14376 119 34942426
Lung infiltration 42.13 20.02 38 14348 12867 34929678
Therapy non-responder 41.87 20.02 65 14321 39081 34903464
Hepatic cytolysis 40.23 20.02 39 14347 14457 34928088
Organising pneumonia 40.16 20.02 27 14359 5952 34936593
Osteomyelitis 38.51 20.02 40 14346 16096 34926449
Lung disorder 37.64 20.02 58 14328 34638 34907907
Myositis 36.40 20.02 34 14352 12036 34930509
Dizziness 35.72 20.02 23 14363 218498 34724047
Vascular pseudoaneurysm thrombosis 33.16 20.02 7 14379 48 34942497
Oliguria 32.03 20.02 27 14359 8353 34934192
Tubulointerstitial nephritis 31.48 20.02 41 14345 20983 34921562
Product administration error 31.15 20.02 36 14350 16308 34926237
Blood culture positive 30.70 20.02 21 14365 4762 34937783
Acute interstitial pneumonitis 29.86 20.02 10 14376 450 34942095
Tremor 29.81 20.02 88 14298 82499 34860046
Rectal perforation 29.45 20.02 10 14376 470 34942075
Kounis syndrome 28.84 20.02 16 14370 2502 34940043
Weight decreased 28.20 20.02 19 14367 176282 34766263
Nausea 27.65 20.02 62 14324 339846 34602699
Myasthenia gravis crisis 26.83 20.02 10 14376 617 34941928
Toxicity to various agents 26.56 20.02 26 14360 200336 34742209
Generalised oedema 26.49 20.02 29 14357 12379 34930166
Endocarditis staphylococcal 26.22 20.02 9 14377 437 34942108
Septic embolus 26.18 20.02 12 14374 1253 34941292
Constipation 25.88 20.02 12 14374 136970 34805575
Endocarditis bacterial 25.83 20.02 11 14375 964 34941581
Stevens-Johnson syndrome 25.83 20.02 35 14351 18604 34923941
Eosinophil count increased 25.56 20.02 24 14362 8548 34933997
Cardiac valve abscess 25.56 20.02 5 14381 22 34942523
Pain 25.50 20.02 28 14358 204647 34737898
Aspergillus infection 25.06 20.02 28 14358 12226 34930319
Renal failure 24.86 20.02 113 14273 130444 34812101
Depression 24.61 20.02 5 14381 97093 34845452
Autoimmune anaemia 24.41 20.02 4 14382 4 34942541
Systemic inflammatory response syndrome 24.38 20.02 21 14365 6688 34935857
Abdominal pain 24.38 20.02 19 14367 163599 34778946
Renal tubular necrosis 24.13 20.02 31 14355 15649 34926896
Hypoperfusion 23.79 20.02 11 14375 1172 34941373
Spinal cord disorder 23.76 20.02 10 14376 851 34941694
Vomiting 23.71 20.02 41 14345 247580 34694965
Acute respiratory distress syndrome 23.51 20.02 40 14346 25929 34916616
Toxic skin eruption 23.26 20.02 26 14360 11359 34931186
Fungaemia 23.24 20.02 14 14372 2554 34939991
Insomnia 23.14 20.02 7 14379 103900 34838645
Chimerism 22.84 20.02 7 14379 236 34942309
Hypertension 22.77 20.02 14 14372 136429 34806116
Gait disturbance 22.39 20.02 4 14382 85136 34857409
Chorioretinitis 22.30 20.02 8 14378 443 34942102
Device related infection 21.83 20.02 31 14355 17206 34925339
Blood creatinine increased 21.78 20.02 87 14299 94889 34847656
Encephalopathy 21.57 20.02 46 14340 35273 34907272
Geotrichum infection 21.43 20.02 8 14378 496 34942049
Asthenia 21.36 20.02 43 14343 245208 34697337
Headache 21.29 20.02 31 14355 200604 34741941
Essential tremor 21.06 20.02 9 14377 795 34941750
Choluria 20.82 20.02 6 14380 163 34942382
Uraemic encephalopathy 20.61 20.02 7 14379 329 34942216
Rash 20.39 20.02 159 14227 222593 34719952
Dysentery 20.04 20.02 7 14379 358 34942187

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eosinophilic pneumonia 1993.75 17.86 424 21117 4886 79717961
Blood creatine phosphokinase increased 1024.42 17.86 450 21091 65640 79657207
Eosinophilia 670.48 17.86 299 21242 45046 79677801
Rhabdomyolysis 523.21 17.86 333 21208 102798 79620049
Drug reaction with eosinophilia and systemic symptoms 509.27 17.86 277 21264 63967 79658880
Eosinophilic pneumonia acute 476.76 17.86 99 21442 999 79721848
Antimicrobial susceptibility test resistant 451.27 17.86 80 21461 308 79722539
Pathogen resistance 384.59 17.86 145 21396 14197 79708650
Acute kidney injury 329.12 17.86 538 21003 518866 79203981
Pulmonary eosinophilia 305.42 17.86 64 21477 677 79722170
Product use in unapproved indication 257.53 17.86 327 21214 250032 79472815
Chills 203.33 17.86 233 21308 160001 79562846
Multiple organ dysfunction syndrome 182.23 17.86 192 21349 120054 79602793
Cardiac valve vegetation 178.94 17.86 43 21498 876 79721971
Agranulocytosis 169.42 17.86 121 21420 44909 79677938
Drug resistance 157.81 17.86 113 21428 42100 79680747
Hypersensitivity pneumonitis 150.08 17.86 51 21490 3688 79719159
Cholestasis 149.36 17.86 119 21422 51990 79670857
Staphylococcal bacteraemia 147.22 17.86 70 21471 12148 79710699
Interstitial lung disease 139.78 17.86 162 21379 112438 79610409
Drug dispensed to wrong patient 132.14 17.86 32 21509 674 79722173
Minimum inhibitory concentration 131.13 17.86 25 21516 155 79722692
Pyrexia 124.80 17.86 434 21107 678275 79044572
Septic shock 114.40 17.86 153 21388 122648 79600199
Bacteraemia 111.63 17.86 83 21458 32741 79690106
Thrombocytopenia 110.47 17.86 230 21311 265029 79457818
Endocarditis 98.80 17.86 51 21490 10546 79712301
Therapeutic response delayed 98.56 17.86 28 21513 1114 79721733
Enterococcal infection 98.15 17.86 58 21483 15602 79707245
Off label use 93.19 17.86 486 21055 906729 78816118
Rash maculo-papular 91.06 17.86 93 21448 55985 79666862
Fatigue 86.23 17.86 75 21466 929652 78793195
Drug ineffective for unapproved indication 85.06 17.86 86 21455 51152 79671695
Sepsis 80.48 17.86 205 21336 269223 79453624
Hepatic cytolysis 77.75 17.86 62 21479 27089 79695758
Encephalopathy 73.76 17.86 91 21450 67306 79655541
Candida infection 72.49 17.86 69 21472 38145 79684702
Wrong patient received product 69.87 17.86 31 21510 4587 79718260
Pain 68.58 17.86 54 21487 703748 79019099
Hepatocellular injury 68.46 17.86 74 21467 47519 79675328
Alveolar lung disease 67.65 17.86 18 21523 559 79722288
Diffuse alveolar damage 67.04 17.86 28 21513 3576 79719271
Arthritis bacterial 65.56 17.86 37 21504 9129 79713718
Fall 65.44 17.86 25 21516 487604 79235243
Headache 65.16 17.86 49 21492 653723 79069124
Pulmonary interstitial emphysema syndrome 64.58 17.86 17 21524 506 79722341
Diarrhoea 62.87 17.86 88 21453 880401 78842446
Rash 62.71 17.86 315 21226 578043 79144804
Staphylococcal infection 59.46 17.86 76 21465 58219 79664628
Intervertebral discitis 59.19 17.86 28 21513 4800 79718047
Toxic epidermal necrolysis 58.39 17.86 66 21475 44515 79678332
Osteomyelitis 57.92 17.86 57 21484 32808 79690039
Tubulointerstitial nephritis 57.72 17.86 61 21480 38174 79684673
Expired product administered 57.41 17.86 31 21510 7020 79715827
Dizziness 57.01 17.86 36 21505 526405 79196442
Pneumonitis 56.88 17.86 76 21465 60784 79662063
Systemic candida 56.04 17.86 30 21511 6676 79716171
Acute respiratory distress syndrome 55.62 17.86 64 21477 44003 79678844
Toxic skin eruption 53.59 17.86 46 21495 22247 79700600
Wrong product administered 52.89 17.86 32 21509 8980 79713867
Lung infiltration 52.50 17.86 46 21495 22866 79699981
Device related infection 52.28 17.86 55 21486 34239 79688608
Blood culture positive 52.24 17.86 31 21510 8398 79714449
Hepatitis cholestatic 51.55 17.86 37 21504 13815 79709032
Myositis 51.13 17.86 42 21499 19126 79703721
Enterococcal bacteraemia 50.98 17.86 22 21519 3046 79719801
Organising pneumonia 49.61 17.86 33 21508 10906 79711941
Blood creatinine increased 49.40 17.86 121 21420 154936 79567911
Neutropenia 49.14 17.86 180 21361 287530 79435317
Eosinophil count increased 48.84 17.86 39 21502 17066 79705781
Septic embolus 48.73 17.86 19 21522 2032 79720815
Alopecia 47.58 17.86 4 21537 231351 79491496
Abdominal discomfort 47.27 17.86 6 21535 250721 79472126
Drug intolerance 45.93 17.86 8 21533 264111 79458736
Respiratory failure 45.24 17.86 129 21412 180782 79542065
Renal failure 45.20 17.86 138 21403 200830 79522017
Aortoenteric fistula 44.93 17.86 10 21531 143 79722704
Acute generalised exanthematous pustulosis 44.34 17.86 37 21504 17217 79705630
Product dispensing error 43.88 17.86 33 21508 13230 79709617
Pancytopenia 43.21 17.86 120 21421 165625 79557222
Symmetrical drug-related intertriginous and flexural exanthema 43.21 17.86 14 21527 872 79721975
Aspergillus infection 42.96 17.86 38 21503 19123 79703724
Acute interstitial pneumonitis 42.57 17.86 15 21526 1208 79721639
Weight decreased 40.22 17.86 23 21518 355175 79367672
Joint swelling 40.02 17.86 14 21527 288632 79434215
Product dose omission issue 39.90 17.86 9 21532 247528 79475319
Myalgia 39.45 17.86 125 21416 185516 79537331
Insomnia 39.34 17.86 9 21532 245161 79477686
Peripheral swelling 39.28 17.86 12 21529 269605 79453242
Lung disorder 38.40 17.86 74 21467 80483 79642364
Nasopharyngitis 37.53 17.86 11 21530 253870 79468977
Vomiting 36.93 17.86 78 21463 665750 79057097
Depression 36.75 17.86 7 21534 216783 79506064
Drug eruption 36.73 17.86 52 21489 43883 79678964
Tremor 36.57 17.86 115 21426 169968 79552879
Treatment failure 36.41 17.86 115 21426 170371 79552476
Abdominal pain upper 36.34 17.86 8 21533 223811 79499036
Renal tubular necrosis 36.12 17.86 39 21502 25000 79697847
Product storage error 36.02 17.86 32 21509 16194 79706653
Weight increased 35.89 17.86 15 21526 277371 79445476
Vascular pseudoaneurysm thrombosis 35.38 17.86 7 21534 54 79722793
Leukopenia 35.07 17.86 89 21452 116424 79606423
Arthralgia 34.26 17.86 64 21477 571739 79151108
Constipation 33.98 17.86 17 21524 283033 79439814
Renal impairment 33.29 17.86 106 21435 157677 79565170
Therapeutic product effect decreased 33.23 17.86 3 21538 163860 79558987
Nausea 33.00 17.86 140 21401 957056 78765791
Stevens-Johnson syndrome 32.22 17.86 46 21495 39120 79683727
Product administration error 31.65 17.86 41 21500 31805 79691042
Contraindicated product administered 31.64 17.86 3 21538 157535 79565312
Therapy non-responder 31.49 17.86 74 21467 92231 79630616
Musculoskeletal stiffness 31.08 17.86 5 21536 175003 79547844
Brain abscess 30.19 17.86 18 21523 4918 79717929
Sinusitis 29.76 17.86 8 21533 195493 79527354
Chorioretinitis 29.63 17.86 11 21530 1029 79721818
Disseminated intravascular coagulation 29.34 17.86 42 21499 35800 79687047
Lactic acidosis 29.18 17.86 61 21480 70298 79652549
Endocarditis bacterial 28.85 17.86 12 21529 1517 79721330
Anxiety 28.25 17.86 16 21525 248496 79474351
Oliguria 28.20 17.86 28 21513 16281 79706566
Syncope 27.97 17.86 7 21534 179442 79543405
Generalised oedema 27.53 17.86 33 21508 23676 79699171
Rectal perforation 27.36 17.86 10 21531 895 79721952
Kounis syndrome 27.19 17.86 16 21525 4266 79718581
Myocarditis 26.47 17.86 31 21510 21702 79701145
Pain in extremity 26.34 17.86 36 21505 364502 79358345
Systemic inflammatory response syndrome 26.22 17.86 23 21518 11442 79711405
Dermatitis exfoliative generalised 26.16 17.86 19 21522 7222 79715625
Autoimmune anaemia 26.10 17.86 4 21537 4 79722843
Cardiac valve abscess 25.70 17.86 5 21536 35 79722812
Gait disturbance 25.60 17.86 12 21529 207494 79515353
Myasthenia gravis crisis 25.36 17.86 10 21531 1101 79721746
Multiple-drug resistance 24.97 17.86 20 21521 8788 79714059
Injection site pain 24.72 17.86 3 21538 129835 79593012
Chimerism 24.39 17.86 7 21534 289 79722558
Osteomyelitis fungal 24.34 17.86 7 21534 291 79722556
Pulmonary toxicity 23.88 17.86 23 21518 12891 79709956
Hypertension 23.59 17.86 33 21508 330959 79391888
Contusion 22.80 17.86 6 21535 148770 79574077
Hypoperfusion 22.60 17.86 12 21529 2627 79720220
Haemorrhagic disorder 21.98 17.86 10 21531 1568 79721279
Splenic embolism 21.97 17.86 6 21535 206 79722641
Endocarditis staphylococcal 21.76 17.86 8 21533 728 79722119
Feeling abnormal 21.58 17.86 8 21533 159191 79563656
Skin test positive 21.43 17.86 9 21532 1165 79721682
Abdominal pain 21.25 17.86 46 21495 389523 79333324
Fungaemia 21.18 17.86 14 21527 4577 79718270
Purpura 20.76 17.86 26 21515 19501 79703346
Gastrointestinal disorder 20.59 17.86 4 21537 122201 79600646
Swelling 20.56 17.86 17 21524 216694 79506153
Spinal cord disorder 20.54 17.86 10 21531 1825 79721022
Hepatitis 20.46 17.86 46 21495 55681 79667166
Vascular device infection 20.33 17.86 19 21522 10257 79712590
Maternal exposure during pregnancy 20.01 17.86 6 21535 136532 79586315
Hypoaesthesia 19.73 17.86 12 21529 179340 79543507
Toxicity to various agents 19.67 17.86 54 21487 421486 79301361
Palpitations 19.61 17.86 5 21536 126605 79596242
Geotrichum infection 19.53 17.86 8 21533 973 79721874
Hyperoxaluria 19.47 17.86 6 21535 317 79722530
Arthritis fungal 19.43 17.86 5 21536 136 79722711
Respiratory distress 19.06 17.86 46 21495 58293 79664554
Decreased appetite 19.03 17.86 40 21501 342378 79380469
Haemodialysis 19.01 17.86 24 21517 18144 79704703
Essential tremor 19.00 17.86 9 21532 1546 79721301
Staphylococcus test positive 18.98 17.86 15 21526 6466 79716381
Mixed liver injury 18.95 17.86 16 21525 7562 79715285
Uraemic encephalopathy 18.60 17.86 7 21534 680 79722167
Gastrooesophageal reflux disease 18.46 17.86 3 21538 104243 79618604
Systemic lupus erythematosus 18.35 17.86 5 21536 121144 79601703
Wound drainage 18.19 17.86 8 21533 1158 79721689
Choluria 18.12 17.86 6 21535 400 79722447
Memory impairment 18.11 17.86 4 21537 111730 79611117
Asthenia 18.08 17.86 74 21467 511615 79211232
Microbiology test abnormal 18.04 17.86 3 21538 7 79722840
Musculoskeletal pain 18 17.86 3 21538 102351 79620496
Asthma 17.95 17.86 7 21534 135088 79587759
Staphylococcal sepsis 17.92 17.86 21 21520 14705 79708142

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XX09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Other antibacterials
FDA CS M0519359 Lipopeptides
FDA EPC N0000175509 Lipopeptide Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:140190 calcium-dependent antibiotic

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Secondary infection of erosion and ulcer caused by MRSA indication 266096002
Secondary infection of surgical wounds caused by MRSA indication 308155002
Right-sided Staphylococcus aureus endocarditis indication 426087004
Bacteremia caused by Staphylococcus aureus indication 428763004
Sepsis due to Staphylococcus aureus indication 448417001
Sepsis caused by methicillin resistant Staphylococcus aureus indication 448812000
Secondary infection of trauma, and burn wounds caused by MRSA indication 1176997000
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection indication
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection indication
Complicated Skin and Skin Structure Streptococcus dysgalactiae Infection indication
Diabetic Foot Infection Due to Gram-Positive Bacteria off-label use
Acute nephropathy contraindication 58574008
Diarrhea contraindication 62315008
Disorder of muscle contraindication 129565002 DOID:423
Eosinophilic asthma contraindication 367542003 DOID:9498
Neuropathy contraindication 386033004 DOID:870
Pseudomembranous enterocolitis contraindication 397683000
Increased Creatine Phosphokinase contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.22 acidic
pKa2 3.62 acidic
pKa3 3.96 acidic
pKa4 4.53 acidic
pKa5 12.39 acidic
pKa6 12.68 acidic
pKa7 12.92 acidic
pKa8 13.25 acidic
pKa9 13.31 acidic
pKa10 13.53 acidic
pKa11 13.68 acidic
pKa12 13.81 acidic
pKa13 13.92 acidic
pKa14 10.43 Basic
pKa15 2.61 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
500MG/VIAL CUBICIN CUBIST PHARMS LLC N021572 Sept. 12, 2003 DISCN POWDER INTRAVENOUS 8003673 Sept. 4, 2028 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
350MG/VIAL DAPTOMYCIN HOSPIRA N210282 June 21, 2021 RX POWDER INTRAVENOUS 10357535 Sept. 11, 2033 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12
350MG/VIAL DAPTOMYCIN HOSPIRA N210282 June 21, 2021 RX POWDER INTRAVENOUS 9655946 Sept. 11, 2033 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18
500MG/VIAL DAPTOMYCIN HOSPIRA N210282 June 21, 2021 RX POWDER INTRAVENOUS 10357535 Sept. 11, 2033 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12
500MG/VIAL DAPTOMYCIN HOSPIRA N210282 June 21, 2021 RX POWDER INTRAVENOUS 9655946 Sept. 11, 2033 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18
500MG/VIAL DAPZURA RT BAXTER HLTHCARE CORP N213645 Jan. 25, 2022 DISCN POWDER INTRAVENOUS 11173189 March 11, 2041 METHOD OF TREATING A BACTERIAL INFECTION BY ADMINISTERING A RECONSTITUTED SOLID FORMULATION OF DAPTOMYCIN CONTAINING 31.0 TO 59.4% WT TOTAL MANNITOL AND SORBITOL

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Outer membrane porin protein OmpD Transporter WOMBAT-PK

External reference:

IDSource
4021414 VUID
N0000148828 NUI
D01080 KEGG_DRUG
22299 RXNORM
4021414 VANDF
C0057144 UMLSCUI
CHEBI:600103 CHEBI
CHEMBL387675 ChEMBL_ID
D017576 MESH_DESCRIPTOR_UI
DB00080 DRUGBANK_ID
10904 IUPHAR_LIGAND_ID
6127 INN_ID
NWQ5N31VKK UNII
21585658 PUBCHEM_CID
17565 MMSL
244166 MMSL
47428 MMSL
d04894 MMSL
003222 NDDF
406438001 SNOMEDCT_US
406439009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 29 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 29 sections
Daptomycin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-0712 INJECTION, SOLUTION 350 mg INTRAVENOUS NDA 27 sections
Daptomycin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-0714 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 27 sections
Daptomycin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-0716 INJECTION, SOLUTION 700 mg INTRAVENOUS NDA 27 sections
Daptomycin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-0718 INJECTION, SOLUTION 1000 mg INTRAVENOUS NDA 27 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0120 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 33 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0120 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 33 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0120 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 33 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0122 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 33 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0122 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 33 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0122 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 33 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-2757 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 34 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-2757 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 34 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-2757 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 34 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-5933 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 33 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0703-0125 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA AUTHORIZED GENERIC 30 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 0703-0125 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA AUTHORIZED GENERIC 30 sections
daptomycin Human Prescription Drug Label 1 0781-3295 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 27 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 16714-892 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 16714-892 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-434 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS ANDA 30 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-434 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS ANDA 30 sections
DAPTOMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16729-435 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 30 sections
DAPTOMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16729-435 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 30 sections
daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-174 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 32 sections
daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-174 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 32 sections
daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-174 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 32 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-179 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 32 sections
Daptomycin HUMAN PRESCRIPTION DRUG LABEL 1 25021-179 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 350 mg INTRAVENOUS NDA 32 sections